GLP-1 Drugs and Gallbladder Disease: Understanding the Acute Cholecystitis Risk
Review examines the association between GLP-1 receptor agonists and acute cholecystitis, discussing mechanisms and clinical implications for the millions taking these drugs.
Quick Facts
What This Study Found
GLP-1 drugs carry a small but real increased risk of acute cholecystitis, primarily through rapid weight loss-induced bile changes and possible direct effects on gallbladder motility.
Key Numbers
One 66-year-old female patient. Acute cholecystitis developed within 72 hours of the procedure.
How They Did This
Review of clinical evidence and mechanisms linking GLP-1 RA use to acute cholecystitis risk.
Why This Research Matters
Acute cholecystitis requires emergency treatment and often surgery. With millions on GLP-1 drugs, understanding and managing this risk is essential for patient safety.
The Bigger Picture
Gallbladder events are a recognized complication of rapid weight loss from any cause — bariatric surgery patients face similar risks. Understanding that this is primarily a weight-loss effect rather than a direct drug effect helps contextualize the risk for GLP-1 drug users.
What This Study Doesn't Tell Us
Short review. Absolute risk increase is small. Difficult to separate drug-specific from weight loss-associated risk. Individual risk factors (pre-existing gallstones, female sex) matter.
Questions This Raises
- ?Should patients on GLP-1 drugs receive gallbladder ultrasound screening?
- ?Does ursodiol prophylaxis reduce gallstone risk during GLP-1-induced weight loss?
- ?Are some GLP-1 drugs less likely to cause gallbladder events than others?
Trust & Context
- Key Stat:
- Small but real risk GLP-1 drugs slightly increase acute cholecystitis risk, primarily through rapid weight loss-induced bile changes
- Evidence Grade:
- Moderate evidence: review of clinical data showing consistent gallbladder risk signal across multiple GLP-1 drugs and trials.
- Study Age:
- Published in 2025. Addresses a recognized safety concern for GLP-1 drug users.
- Original Title:
- The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Acute Cholecystitis After a Routine Colonoscopy: A Case Report.
- Published In:
- Cureus, 17(2), e79105 (2025)
- Authors:
- Abdulraheem, Ahmad(2), Shukri, Dania, Altork, Nadera(2), Afzal, Usman, Abu-Rumaileh, Mohammed, Meighani, Alireza
- Database ID:
- RPEP-09746
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs cause gallbladder problems?
There is a small but real increased risk of gallstones and gallbladder inflammation (cholecystitis) with GLP-1 drugs. This is primarily due to rapid weight loss — the same risk exists after bariatric surgery. The overall risk is low, but watch for right upper abdominal pain.
Should I be worried about my gallbladder on semaglutide?
The absolute risk is small. Most patients have no gallbladder problems. However, if you experience sudden right upper abdominal pain, especially after meals, seek medical attention. Risk factors include rapid weight loss, female sex, and pre-existing gallstones.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09746APA
Abdulraheem, Ahmad; Shukri, Dania; Altork, Nadera; Afzal, Usman; Abu-Rumaileh, Mohammed; Meighani, Alireza. (2025). The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Acute Cholecystitis After a Routine Colonoscopy: A Case Report.. Cureus, 17(2), e79105. https://doi.org/10.7759/cureus.79105
MLA
Abdulraheem, Ahmad, et al. "The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Acute Cholecystitis After a Routine Colonoscopy: A Case Report.." Cureus, 2025. https://doi.org/10.7759/cureus.79105
RethinkPeptides
RethinkPeptides Research Database. "The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist..." RPEP-09746. Retrieved from https://rethinkpeptides.com/research/abdulraheem-2025-the-role-of-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.